CancerDrs

Prostate Cancer clinical trials in Oregon

26 actively recruiting prostate cancer trials at 15 sites across Oregon.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full prostate cancer transparency page →

Phase 3 Recruiting Academic/Other

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …

Sponsor: NRG Oncology
NCT ID: NCT05946213
Sites in Oregon:
  • Saint Charles Health System — Bend, Oregon
  • Clackamas Radiation Oncology Center — Clackamas, Oregon
  • Providence Portland Medical Center — Portland, Oregon
  • Providence Saint Vincent Medical Center — Portland, Oregon
  • Kaiser Permanente Northwest — Portland, Oregon
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial

This phase III trial studies whether adding apalutamide to the usual treatment improves outcome in patients with lymph node positive prostate cancer after surgery. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tum…

Sponsor: NRG Oncology
NCT ID: NCT04134260
Sites in Oregon:
  • Legacy Mount Hood Medical Center — Gresham, Oregon
  • Legacy Good Samaritan Hospital and Medical Center — Portland, Oregon
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation ther…

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT04423211
Sites in Oregon:
  • Saint Charles Health System — Bend, Oregon
  • Clackamas Radiation Oncology Center — Clackamas, Oregon
  • Providence Cancer Institute Clackamas Clinic — Clackamas, Oregon
  • Bay Area Hospital — Coos Bay, Oregon
  • Legacy Mount Hood Medical Center — Gresham, Oregon
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT03678025
Sites in Oregon:
  • Legacy Mount Hood Medical Center — Gresham, Oregon
  • Legacy Good Samaritan Hospital and Medical Center — Portland, Oregon
  • Oregon Health and Science University — Portland, Oregon
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…

Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in Oregon:
  • Saint Alphonsus Cancer Care Center-Baker City — Baker City, Oregon
  • Saint Charles Health System — Bend, Oregon
  • Clackamas Radiation Oncology Center — Clackamas, Oregon
  • Bay Area Hospital — Coos Bay, Oregon
  • Providence Hood River Memorial Hospital — Hood River, Oregon
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body

This phase III trial compares the effect of adding carboplatin to the standard of care chemotherapy drug cabazitaxel versus cabazitaxel alone in treating prostate cancer that keeps growing even when the amount of testosterone in the body i…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT06470243
Sites in Oregon:
  • Saint Alphonsus Cancer Care Center-Baker City — Baker City, Oregon
  • Saint Alphonsus Cancer Care Center-Ontario — Ontario, Oregon
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC.

Sponsor: AstraZeneca
NCT ID: NCT06120491
Sites in Oregon:
  • Research Site — Florence, Oregon
  • Research Site — Portland, Oregon
  • Research Site — Portland, Oregon
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate Cancer.

Sponsor: Celgene
NCT ID: NCT06764485
Sites in Oregon:
  • Providence Portland Medical Center — Portland, Oregon
  • Providence St. Vincent Medical Center — Portland, Oregon
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in combination with best supportive care (BSC) as compared to placebo with…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07164443
Sites in Oregon:
  • Compass Oncology — Portland, Oregon
  • Oregon Urology Institute — Springfield, Oregon
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) i…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136624
Sites in Oregon:
  • Oregon Health and Science University ( Site 0028) — Portland, Oregon
  • VA Portland Health Care System ( Site 0058) — Portland, Oregon
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in particip…

Sponsor: AstraZeneca
NCT ID: NCT06952803
Sites in Oregon:
  • Research Site — Springfield, Oregon
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans) when …

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07225946
Sites in Oregon:
  • Oregon Urology Institute — Springfield, Oregon
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

The purpose of this study is to evaluate the efficacy and safety of 177Lu-TLX591 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with Androgen Receptor Pathway Inhibitor Treatment

Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited
NCT ID: NCT06520345
Sites in Oregon:
  • OHSU Knight Cancer Center — Portland, Oregon
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

This phase II trial evaluates whether genetic testing in prostate cancer is helpful in deciding which study treatment patients are assigned. Patient cancer tissue samples are obtained from a previous surgery or biopsy procedure and tested …

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06632977
Sites in Oregon:
  • Providence Portland Medical Center — Portland, Oregon
  • Providence Saint Vincent Medical Center — Portland, Oregon
  • Oregon Health and Science University — Portland, Oregon
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…

Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Oregon:
  • Oregon Health & Science University (OHSU) — Portland, Oregon
View on ClinicalTrials.gov →
Phase 2 Recruiting Federal

High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers

This study will determine whether the presence of DNA repair deficiency in the form of alterations in the genes ATM, CDK12 or CHEK2 predicts for a high likelihood of responding to the use of intermittent high dose testosterone. This therap…

Sponsor: VA Office of Research and Development
NCT ID: NCT05011383
Sites in Oregon:
  • VA Portland Health Care System, Portland, OR — Portland, Oregon
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer

This is an open-label, randomized, Phase 2b study of ZEN003694 in combination with enzalutamide vs. enzalutamide monotherapy in patients with mCRPC who have progressed on prior abiraterone by PCWG3 criteria. Disease must have progressed on…

Sponsor: Zenith Epigenetics
NCT ID: NCT04986423
Sites in Oregon:
  • Northwest Cancer Specialists, P.C. — Portland, Oregon
View on ClinicalTrials.gov →
Phase 2 Recruiting Federal

A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss

The purpose of this study is to learn about how an investigational drug intervention completed before doing prostate surgery (specifically, radical prostatectomy with lymph node dissection) may help in treatment of high risk localized pros…

Sponsor: VA Office of Research and Development
NCT ID: NCT05593497
Sites in Oregon:
  • VA Portland Health Care System, Portland, OR — Portland, Oregon
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 in adults with metastatic castration-resistant p…

Sponsor: Janux Therapeutics
NCT ID: NCT05519449
Sites in Oregon:
  • Oregon Health and Science University — Portland, Oregon
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer

The purpose of Parts 1, 2A, and 2B of the study is to determine the recommended regimen for Phase 2 (RP2Rs) of combination of JNJ-87189401 with JNJ-78278343 and the purpose of Part 2C of this study is to determine how safe the RP2R(s) of t…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06095089
Sites in Oregon:
  • Oregon Health And Science University — Portland, Oregon
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of MGC026 in Participants With Advanced Solid Tumors

The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tu…

Sponsor: MacroGenics
NCT ID: NCT06242470
Sites in Oregon:
  • Providence Cancer Institute — Portland, Oregon
View on ClinicalTrials.gov →
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Oregon:
  • Saint Alphonsus Cancer Care Center-Baker City — Baker City, Oregon
  • Saint Charles Health System — Bend, Oregon
  • Clackamas Radiation Oncology Center — Clackamas, Oregon
  • Providence Cancer Institute Clackamas Clinic — Clackamas, Oregon
  • Bay Area Hospital — Coos Bay, Oregon
View on ClinicalTrials.gov →
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Oregon:
  • Massive Bio SYNERGY-AI site — Portland, Oregon
View on ClinicalTrials.gov →
Recruiting NIH

Precision-Based Genomics in Prostate Cancer

Background: Prostate cancer is the most common cancer and the second leading cause of death in males in the United States. Researchers want to find additional gene mutations that may increase a man s risk for prostate cancer and may affect…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04706663
Sites in Oregon:
  • Oregon Health Sciences University — Portland, Oregon
View on ClinicalTrials.gov →

Showing 25 of 26 trials with sites in Oregon. See all prostate cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-05-25